- The preclinical study result of Aimed-GeneQuantum co-developing 'FGFR3-ADC' "AMB302/GQ1011" will be presented at the "World ADC".
- They have confirmed AMB302/GQ1011's anti-tumor effect in both bladder cancer and GBM cancer models, and plan to submit IND and start phase 1 clinical trial in 1H 2024.
Link to full news: http://www.biospectator.com/view/news_view.php?varAtcId=18498